Satoru Asahi

1.5k citations

52 papers · 1.3k indexed · h-index 16

Pharmacology top 0.5%
Oncology top 10%
Molecular Biology
Pediatrics, Perinatology and Child Health top 5%
Pulmonary and Respiratory Medicine

Co-authors: Tsuyoshi Yokoi Toshiyuki Takeuchi Hiroshi Yamazaki Sumie Yoshitomi Tomoko Komatsu Miki Katoh Noriaki Shimada Tsutomu Shimada
Topics: Drug Transport and Resistance Mechanisms (18 papers)Pharmacogenetics and Drug Metabolism (12 papers)Pharmacological Effects and Toxicity Studies (7 papers)
Cited by: Pharmacology Oncology Biochemistry
Journals: Cancer Research Journal of Medicinal Chemistry Applied Microbiology and Biotechnology
Partner nations: Japan United States China

In The Last Decade

Satoru Asahi

52 papers receiving 1.3k citations

Peers

Countries citing papers authored by Satoru Asahi

Since Specialization

Citations

This map shows the geographic impact of Satoru Asahi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoru Asahi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoru Asahi more than expected).

Fields of papers citing papers by Satoru Asahi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoru Asahi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoru Asahi. The network helps show where Satoru Asahi may publish in the future.

Co-authorship network of co-authors of Satoru Asahi

This figure shows the co-authorship network connecting the top 25 collaborators of Satoru Asahi. A scholar is included among the top collaborators of Satoru Asahi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoru Asahi. Satoru Asahi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice 2020 ·Pharmaceutical Research ·Tomoki Yoneyama,Sho Sato,(unknown),Rosa Fradley,(unknown),(unknown),(unknown),Toshal R. Patel,Yoshihiko Tagawa,Toshiya Moriwaki,Satoru Asahi	7
2	The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats 2019 ·Drug Metabolism and Disposition ·(unknown),(unknown),Yoshihiko Tagawa,Akio Morohashi,Takahiro Kondo,Satoru Asahi,Leslie Z. Benet	5
3	Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation 2017 ·Biopharmaceutics & Drug Disposition ·Akihiko Goto,Yoshihiko Tagawa,(unknown),Sho Sato,M. Yamamoto,Takeshi Wakabayashi,Tetsuya Tsukamoto,Joost DeJongh,Tamara J. van Steeg,Toshiya Moriwaki,Satoru Asahi	1
4	Long-Term Stability of Cryopreserved Human Hepatocytes: Evaluation of Phase I and II Drug-Metabolizing Enzyme Activities and CYP3A4/5 Induction for More than a Decade 2017 ·Drug Metabolism and Disposition ·(unknown),Mitsuhiro Nishihara,Junzo Takahashi,Satoru Asahi	6
5	Mechanism for Covalent Binding of MLN3126, an Oral Chemokine C-C Motif Receptor 9 Antagonist, to Serum Albumins 2017 ·Drug Metabolism and Disposition ·(unknown),Akio Morohashi,Kimio Tohyama,Toshiyuki Takeuchi,Yoshihiko Tagawa,Takahiro Kondo,Satoru Asahi	4
6	UDP-glucuronosyltransferase 2B15 (UGT2B15) Is the Major Enzyme Responsible for Sipoglitazar Glucuronidation in Humans: Retrospective Identification of the UGT Isoform by In Vitro Analysis and the Effect of UGT2B152 Mutation 2013 ·Drug Metabolism and Pharmacokinetics* ·Mitsuhiro Nishihara,(unknown),(unknown),Junzo Takahashi,Satoru Asahi	6
7	Pharmacokinetic and Pharmacodynamic Modeling of Hedgehog Inhibitor TAK-441 for the Inhibition of Gli1 messenger RNA Expression and Antitumor Efficacy in Xenografted Tumor Model Mice 2013 ·Drug Metabolism and Disposition ·Akifumi Kogame,Yoshihiko Tagawa,Sachio Shibata,Hideaki Tojo,Maki Miyamoto,Kimio Tohyama,Takahiro Kondo,Shimoga R. Prakash,Wen Chyi Shyu,Satoru Asahi	15
8	Evaluation of low background liquid scintillation counter for non-clinical ADME studies 2012 ·Xenobiotica ·(unknown),Akifumi Kogame,Yoshihiko Tagawa,Takahiro Kondo,Satoru Asahi	1
9	Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys 2012 ·The Journal of Steroid Biochemistry and Molecular Biology ·Masuo Yamaoka,Takahito Hara,Takenori Hitaka,Tomohiro Kaku,Toshiyuki Takeuchi,Junzo Takahashi,Satoru Asahi,Hiroshi Miki,Akihiro Tasaka,Masami Kusaka	98
10	Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals 2012 ·Xenobiotica ·(unknown),(unknown),Toshiyuki Takeuchi,Akio Morohashi,Hitomi Yamasaki,Yoshihiko Tagawa,Junzo Takahashi,Takahiro Kondo,Satoru Asahi	9
11	Differences in the Pharmacokinetics of 4-Amino-3-Chlorophenyl Hydrogen Sulfate, a Metabolite of Resatorvid, in Rats and Dogs 2011 ·Drug Metabolism and Disposition ·(unknown),Toshiyuki Takeuchi,Yoshihiko Tagawa,Takahiro Kondo,Tomoo Itoh,Satoru Asahi	3
12	An Unusual Metabolic Pathway of Sipoglitazar, a Novel Antidiabetic Agent: Cytochrome P450-Catalyzed Oxidation of Sipoglitazar Acyl Glucuronide 2011 ·Drug Metabolism and Disposition ·Mitsuhiro Nishihara,(unknown),(unknown),Junzo Takahashi,(unknown),Takahiro Kondo,Satoru Asahi	10
13	Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer 2011 ·Bioorganic & Medicinal Chemistry ·Tomohiro Kaku,Takenori Hitaka,Akio Ojida,Nobuyuki Matsunaga,(unknown),Toshimasa Tanaka,Takahito Hara,Masuo Yamaoka,Masami Kusaka,Teruaki Okuda,Satoru Asahi,Shuichi Furuya,Akihiro Tasaka	103
14	Advantages of Human Hepatocyte-Derived Transformants Expressing a Series of Human Cytochrome P450 Isoforms for Genotoxicity Examination 2010 ·Toxicological Sciences ·(unknown),Sumie Yoshitomi,Satoru Asahi,(unknown),(unknown),Fumio Chatani,Hiroaki Oda	27
15	In vitro micronucleus test in HepG2 transformants expressing a series of human cytochrome P450 isoforms with chemicals requiring metabolic activation 2009 ·Mutation Research/Genetic Toxicology and Environmental Mutagenesis ·(unknown),Sumie Yoshitomi,Satoru Asahi,(unknown),Fumio Chatani,Hiroaki Oda	23
16	Hypothermia enhances heat-shock protein 70 production in ischemic brains 2009 ·Neuroreport ·Yasuko Terao,Saku Miyamoto,Kazuko Hirai,Hidenori Kamiguchi,Hiroyuki Ohta,Masato Shimojo,Yoshihiro Kiyota,Satoru Asahi,Yasufumi Sakura,Yasushi Shintani	27
17	Roles of NADPH-P450 Reductase and Apo- and Holo-Cytochrome b5 on Xenobiotic Oxidations Catalyzed by 12 Recombinant Human Cytochrome P450s Expressed in Membranes of Escherichia coli 2002 ·Protein Expression and Purification ·Hiroshi Yamazaki,(unknown),Tomoko Komatsu,Katsuhiro Ohyama,(unknown),Satoru Asahi,Noriaki Shimada,F. Peter Guengerich,Tsutomu Shimada,Miki Nakajima,Tsuyoshi Yokoi	206
18	Effects of Homoserine Dehydrogenase Deficiency on Production of Cytidine by Mutants ofBacillus subtilis 1996 ·Bioscience Biotechnology and Biochemistry ·Satoru Asahi,(unknown),(unknown)	12
19	A 3-Deazauracil-resistant Mutant ofBacillus subtiliswith Increased Production of Cytidine 1995 ·Bioscience Biotechnology and Biochemistry ·Satoru Asahi,(unknown),Motowo Izawa,(unknown)	9
20	Vitamin K_2 (Menaquinone) : Screening of Producing Microorganisms and Production by Flavobacterium meningosepticum : 1984 ·Journal of Fermentation Technology ·Yoshiki Tani,Satoru Asahi,Hideaki Yamada	14

About Satoru Asahi

Satoru Asahi is a scholar working on Pharmacology, Oncology and Biochemistry, having authored 52 papers that have together received 1.3k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (18 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Pharmacological Effects and Toxicity Studies (7 papers). The work is most often cited by research in Pharmacology (455 citations), Oncology (449 citations) and Biochemistry (89 citations). Satoru Asahi has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Tsuyoshi Yokoi, Toshiyuki Takeuchi, Hiroshi Yamazaki, Sumie Yoshitomi, Tomoko Komatsu, Miki Katoh, Noriaki Shimada, Tsutomu Shimada, Miki Nakajima and Junzo Takahashi. Their work appears in journals such as Cancer Research, Journal of Medicinal Chemistry and Applied Microbiology and Biotechnology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact